SCHEMBL16947985

SCHEMBL16947985

COC(=O)c1ccc2ccc(N)nc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.52
KDM4E B2RXH2 4/20 0.51
MAPT P10636 3/20 0.51
ALDH1A1 P00352 3/20 0.51
GLA P06280 1/20 0.51
GAA P10253 1/20 0.51
HPGD P15428 1/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51
ATM Q13315 1/20 0.51
HSD17B10 Q99714 1/20 0.51
HTT P42858 2/20 0.49
ALOX15 P16050 1/20 0.49
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
XDH P47989 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23535667 0.89 HTT (0.59) PLAUKDM4EMAPTALDH1A1GLA
SCHEMBL30159696 0.89 HTT (0.59) PLAUKDM4EMAPTALDH1A1GLA
SCHEMBL14332636 0.83 L3MBTL1 (0.50) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL9945611 0.81 KDM4E (0.51) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL31435439 0.81 KDM4E (0.51) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL4403749 0.81 PLAU (0.52) PLAUKDM4EMAPTALDH1A1GLA
SCHEMBL25977852 0.80 HTT (0.49) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL24635160 0.80 HTT (0.49) KDM4EMAPTALDH1A1GLAGAA
SCHEMBL2671555 0.79 PLAU (0.57) PLAUKDM4EMAPTALDH1A1GAA
SCHEMBL13738672 0.78 ALDH1A1 (0.49) KDM4EMAPTALDH1A1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9783500-B2 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition NORTHWESTERN UNIVERSITY (US) 2017-10-10 US disclosed
US-9663468-B2 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition NORTHWESTERN UNIVERSITY (US) 2017-05-30 US disclosed
US-20160368877-A1 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-22 US disclosed
US-20160096806-A1 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-04-07 US disclosed
US-9212144-B2 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition NORTHWESTERN UNIVERSITY (US) 2015-12-15 US disclosed
US-20150210644-A1 2-AMINOQUINOLINE-BASED COMPOUNDS FOR POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITION NORTHWESTERN UNIVERSITY 2015-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368877-A1 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition NOS2, NOS3, NOS1 PLAU 4226/4885KDM4E 880/4885MAPT 882/4885
US-20150210644-A1 2-AMINOQUINOLINE-BASED COMPOUNDS FOR POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITION NOS2, NOS3, NOS1 PLAU 4226/4885KDM4E 880/4885MAPT 882/4885
US-20160096806-A1 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition NOS2, NOS3, NOS1 PLAU 4226/4885KDM4E 880/4885MAPT 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.